Business Practice
CME/CE
Subscribe
BIOSIMILAR APPROVALS
AAAAI Annual Meeting
Celltrion Biosimilar Demonstrates Equivalence With Xolair in Phase 1 Study
March 14th 2022A phase 1 study testing Celltrion Healthcare’s omalizumab biosimilar in healthy subjects showed similar safety and pharmacokinetic profiles to the reference product (Xolair), as presented at the American Academy of Allergy Asthma and Immunology’s annual meeting.
